OpenAI has announced its alignment with the EU AI Act's General-Purpose AI (GPAI) Code, focusing on safety, security, and transparency. The company has contributed to the GPAI Code and the Transparency Code, which set standards for AI models in the EU. OpenAI's practices, such as pre-release testing and public model specifications, demonstrate its commitment to these standards. The company is also addressing content provenance challenges with mechanisms like Content Credentials and SynthID watermarking. This move reflects OpenAI's proactive approach to meeting EU regulatory requirements.
Read originalStanford's Evo 2 AI model has made a significant leap in synthetic biology by generating phages that effectively target E. coli. This breakthrough demonstrates the potential of AI to design entire viral genomes, moving beyond simple DNA edits. The model produced thousands of candidate genomes, with 16 showing strong E. coli-killing activity in lab tests. By releasing Evo 2 as open-source software, Stanford is inviting further exploration and innovation in genome design, potentially paving the way for new treatments against resistant bacteria like MRSA.
Alibaba is testing a new business model for its upcoming Qwen open-weight AI model, introducing revenue-sharing terms for commercial users. This move targets larger companies that profit from offering the model as a service, requiring them to enter a commercial agreement with Alibaba. The approach mirrors the licensing model used by Moonshot for its Kimi K3 model, which includes revenue-sharing for companies exceeding certain revenue thresholds. This shift signifies Alibaba's strategy to monetize its open-weight models while maintaining their open-source nature, potentially setting a precedent for other AI developers.